公开(公告)号：EP3089977A1

公开(公告)日：2016-11-09

申请号：EP15733170.3

申请日：2015-01-02

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： LEE, Changsik ,  YANG, Hyun-Mo ,  KIM, Dohoon ,  BAE, Miseon ,  CHOI, Youngil ,  HA, Nina

IPC分类号： C07D413/06 ,  A61K31/5377 ,  A61P37/00 ,  A61P3/10

CPC分类号： C07D209/20 ,  C07D209/10 ,  C07D401/06 ,  C07D401/08 ,  C07D401/14 ,  C07D403/06 ,  C07D405/14 ,  C07D417/14 ,  C07D471/04

摘要： The present invention provides a novel indole derivative compound, an isomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof. The compound according to the present invention can selectively inhibit histone deacetylase (HDAC), and thus can be used to effectively treat a disease associated with histone deacetylase (HDAC) activity.

公开(公告)号：EP3080125B1

公开(公告)日：2018-10-10

申请号：EP14869323.7

申请日：2014-12-12

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： LEE, Changsik ,  YANG, Hyun-mo ,  LEE, Changkon ,  BAE, Miseon ,  KIM, Soyoung ,  CHOI, Youngil ,  HA, Nina ,  LEE, Jaekwang ,  OH, Jungtaek ,  SONG, Hyeseung ,  KIM, Ilhyang ,  CHOI, Daekyu ,  MIN, Jaeki ,  LIM, Hyojin ,  BAE, Daekwon

IPC分类号： C07D471/04 ,  C07D519/00 ,  A61K31/437 ,  A61P35/00

CPC分类号： C07D471/04 ,  C07D519/00

摘要： The present invention relates to novel azaindole derivatives, and more particularly, to novel azaindole derivatives having histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, the use thereof for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the pharmaceutical compositions, and methods for preparing the novel azaindole derivatives. The novel azaindole derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be used as agents for treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases.

公开(公告)号：EP3116859B1

公开(公告)日：2018-08-01

申请号：EP15762410.7

申请日：2015-03-12

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： SONG, Hyeseung ,  LEE, Changgon ,  KWAK, Dalyong ,  LEE, Jaeyoung ,  BAE, Suyeal ,  KIM, Yuntae ,  BAE, Daekwon ,  HA, Nina ,  BAE, Miseon ,  KIM, Jihyun

IPC分类号： C07D241/12 ,  A61K31/496 ,  A61P29/00 ,  C07D241/04

CPC分类号： C07D241/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D403/10 ,  C07D403/12 ,  C07D405/06 ,  C07D405/10 ,  C07D405/12 ,  C07D409/06 ,  C07D409/10 ,  C07D413/06

摘要： The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.

公开(公告)号：EP3116859A1

公开(公告)日：2017-01-18

申请号：EP15762410.7

申请日：2015-03-12

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： SONG, Hyeseung ,  LEE, Changgon ,  KWAK, Dalyong ,  LEE, Jaeyoung ,  BAE, Suyeal ,  KIM, Yuntae ,  BAE, Daekwon ,  HA, Nina ,  BAE, Miseon ,  KIM, Jihyun

IPC分类号： C07D241/12 ,  A61K31/496 ,  A61P29/00 ,  C07D241/04

CPC分类号： C07D241/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D403/10 ,  C07D403/12 ,  C07D405/06 ,  C07D405/10 ,  C07D405/12 ,  C07D409/06 ,  C07D409/10 ,  C07D413/06

摘要： The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.

摘要翻译： 本发明涉及具有组蛋白脱乙酰酶6（HDAC6）抑制活性的新化合物，其异构体或其药学上可接受的盐，其在制备治疗药物中的用途，包含其的药物组合物，使用该组合物治疗疾病的方法 以及制备该新化合物的方法。 根据本发明的新化合物具有组蛋白脱乙酰酶6（HDAC6）抑制活性，并且可有效预防或治疗HDAC6相关疾病，包括癌症，炎性疾病，自身免疫疾病，神经疾病和神经变性疾病。

公开(公告)号：EP3328844A1

公开(公告)日：2018-06-06

申请号：EP16830838.5

申请日：2016-07-27

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： LEE, Jaekwang ,  HAN, Younghue ,  KIM, Yuntae ,  MIN, Jaeki ,  BAE, Miseon ,  KIM, Dohoon ,  JIN, Seokmin ,  KYUNG, Jangbeen

IPC分类号： C07D271/10 ,  C07D413/12 ,  A61K31/4245 ,  A61K31/18

CPC分类号： C07D271/10 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D471/10

摘要： The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.

公开(公告)号：EP3328843A1

公开(公告)日：2018-06-06

申请号：EP16830836.9

申请日：2016-07-27

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： LEE, Jaekwang ,  HAN, Younghue ,  KIM, Yuntae ,  CHOI, Daekyu ,  MIN, Jaeki ,  BAE, Miseon ,  YANG, Hyunmo ,  KIM, Dohoon

IPC分类号： C07D271/10 ,  C07D413/10 ,  C07D413/12 ,  A61K31/4245 ,  A61K31/18

CPC分类号： C07D271/10 ,  A61P25/00 ,  A61P35/00 ,  A61P37/00 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D513/04

摘要： The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.

公开(公告)号：EP3080125A1

公开(公告)日：2016-10-19

申请号：EP14869323.7

申请日：2014-12-12

申请人： Chong Kun Dang Pharmaceutical Corp.

发明人： LEE, Changsik ,  YANG, Hyun-mo ,  LEE, Changkon ,  BAE, Miseon ,  KIM, Soyoung ,  CHOI, Youngil ,  HA, Nina ,  LEE, Jaekwang ,  OH, Jungtaek ,  SONG, Hyeseung ,  KIM, Ilhyang ,  CHOI, Daekyu ,  MIN, Jaeki ,  LIM, Hyojin ,  BAE, Daekwon

IPC分类号： C07D471/04 ,  C07D487/04 ,  C07D401/04 ,  A61K31/437

CPC分类号： C07D471/04 ,  C07D519/00

摘要： The present invention relates to novel azaindole derivatives, and more particularly, to novel azaindole derivatives having histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, the use thereof for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the pharmaceutical compositions, and methods for preparing the novel azaindole derivatives. The novel azaindole derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be used as agents for treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases.

摘要翻译： 本发明涉及新颖的氮杂吲哚衍生物，更具体地说，涉及具有组蛋白脱乙酰酶（HDAC）抑制活性的新型氮杂吲哚衍生物，其异构体，药学上可接受的盐，其水合物或溶剂合物，其用于制备药物组合物的用途， 含有该组合物的药物组合物，使用该药物组合物治疗疾病的方法，以及制备该新颖的氮杂吲哚衍生物的方法。 根据本发明的新颖的氮杂吲哚衍生物是选择性组蛋白脱乙酰酶（HDAC）抑制剂，可用作治疗恶性肿瘤疾病，炎症性疾病，类风湿性关节炎和神经变性疾病的药剂。